PANCREATIC CANCER

OSL’s Pancreatic Cancer Treatment Approved for Sale in Europe

Next Investors Archived May 05, 2020

OncoSil Medical (ASX:OSL) has received CE Mark approval to market and sell its breakthrough implantable radiotherapy treatment for pancreatic cancer in the EU and UK.

OncoSil™ receives CE Mark approval

Finfeed Archived Apr 01, 2020

OncoSil Medical Ltd (ASX: OSL) has received CE Marking approval from the British Standards Institute (BSI) for its OncoSil™ device.

OncoSil granted FDA Breakthrough Device Designation

Finfeed Archived Mar 18, 2020

OncoSil Medical Ltd’s (ASX: OSL) OncoSil™ device has reached a significant milestone, receiving Breakthrough Device Designation by the US FDA for the treatment of unresectable locally advanced pancreatic cancer.